Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBAY CymaBay Therapeutics	$32.48	$32.44	$7.26 ▼ $32.50	$3.73B	0.32	4.11 million shs	73 shs
CLSD Clearside Biomedical	$0.83 -0.2%	$0.82	$0.70 ▼ $1.65	$64.30M	2.05	360,616 shs	47,820 shs
CYCN Cyclerion Therapeutics	$3.26 -1.2%	$3.12	$1.27 ▼ $9.47	$10.47M	1.55	908,757 shs	11,656 shs
EPIX ESSA Pharma	$1.87 +0.5%	$1.71	$1.40 ▼ $7.88	$83.01M	1.56	191,097 shs	827,986 shs
RDHL Redhill Biopharma	$1.91 -12.4%	$1.92	$1.71 ▼ $20.28	$4.38M	4.22	163,598 shs	26,808 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBAY CymaBay Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
CLSD Clearside Biomedical	-6.32%	+1.72%	+3.62%	+0.88%	-33.68%
CYCN Cyclerion Therapeutics	-9.34%	+6.80%	+6.11%	+22.68%	-0.60%
EPIX ESSA Pharma	+8.77%	+9.41%	+11.38%	+14.11%	-65.43%
RDHL Redhill Biopharma	-0.46%	+5.83%	+24.57%	+2.35%	-99.10%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	2.0174 of 5 stars	3.5	3.0	0.0	0.0	3.1	0.0	0.0
CYCN Cyclerion Therapeutics	2.018 of 5 stars	0.0	5.0	0.0	0.0	3.3	3.3	0.0
EPIX ESSA Pharma	1.1085 of 5 stars	1.0	2.0	0.0	0.0	2.8	2.5	1.3
RDHL Redhill Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBAY CymaBay Therapeutics	0.00	N/A	N/A	N/A
CLSD Clearside Biomedical	3.00	Buy	$4.75	474.09% Upside
CYCN Cyclerion Therapeutics	0.00	N/A	N/A	N/A
EPIX ESSA Pharma	2.00	Hold	$2.00	6.95% Upside
RDHL Redhill Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CLSD, CBAY, EPIX, CYCN, and RDHL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $5.00
5/16/2025	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00 ➝ $5.00
5/15/2025	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBAY CymaBay Therapeutics	$31.07M	119.92	N/A	N/A	$2.58 per share	12.59
CLSD Clearside Biomedical	$1.66M	38.73	N/A	N/A	($0.51) per share	-1.62
CYCN Cyclerion Therapeutics	$2M	5.23	N/A	N/A	$3.27 per share	1.00
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$2.81 per share	N/A
RDHL Redhill Biopharma	$8.04M	0.55	N/A	N/A	($3.66) per share	-0.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBAY CymaBay Therapeutics	-$105.37M	-$0.97	N/A	N/A	N/A	N/A	-50.72%	-31.04%	N/A
CLSD Clearside Biomedical	-$34.35M	-$0.41	N/A	N/A	N/A	-818.57%	N/A	-114.23%	8/11/2025 (Estimated)
CYCN Cyclerion Therapeutics	-$3.06M	-$1.16	N/A	∞	N/A	N/A	-34.02%	-30.68%	8/6/2025 (Estimated)
EPIX ESSA Pharma	-$28.54M	-$0.63	N/A	N/A	N/A	N/A	-23.48%	-22.86%	8/4/2025 (Estimated)
RDHL Redhill Biopharma	-$8.27M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest CLSD, CBAY, EPIX, CYCN, and RDHL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	CLSD Clearside Biomedical	-$0.12	N/A	N/A	N/A	$0.50 million	N/A
8/4/2025	Q3 2025	EPIX ESSA Pharma	-$0.2430	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	CLSD Clearside Biomedical	-$0.12	-$0.11	+$0.01	-$0.11	$0.20 million	$2.33 million
5/8/2025	Q2 2025	EPIX ESSA Pharma	-$0.19	-$0.14	+$0.05	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
CYCN Cyclerion Therapeutics	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
RDHL Redhill Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBAY CymaBay Therapeutics	N/A	10.96	10.96
CLSD Clearside Biomedical	N/A	3.19	3.19
CYCN Cyclerion Therapeutics	N/A	4.21	4.21
EPIX ESSA Pharma	N/A	67.15	67.15
RDHL Redhill Biopharma	N/A	0.54	0.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CBAY CymaBay Therapeutics	95.03%
CLSD Clearside Biomedical	18.75%
CYCN Cyclerion Therapeutics	75.62%
EPIX ESSA Pharma	75.12%
RDHL Redhill Biopharma	7.20%

Insider Ownership

Company	Insider Ownership
CBAY CymaBay Therapeutics	7.00%
CLSD Clearside Biomedical	6.20%
CYCN Cyclerion Therapeutics	34.30%
EPIX ESSA Pharma	15.50%
RDHL Redhill Biopharma	6.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CBAY CymaBay Therapeutics	101	114.72 million	106.69 million	Optionable
CLSD Clearside Biomedical	30	77.71 million	72.89 million	Optionable
CYCN Cyclerion Therapeutics	30	3.21 million	2.11 million	No Data
EPIX ESSA Pharma	50	44.39 million	37.51 million	Optionable
RDHL Redhill Biopharma	210	2.30 million	2.14 million	No Data

CLSD, CBAY, EPIX, CYCN, and RDHL Headlines

Recent News About These Companies

RedHill initiates recruitment for expanded Phase 2 opaganib/darolutamide study

July 2, 2025 | msn.com

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

July 1, 2025 | prnewswire.com

RedHill Biopharma Ltd. (RDHL) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RedHill Biopharma Ltd. (RDHL) Income Statement - Yahoo Finance

June 26, 2025 | finance.yahoo.com

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

May 13, 2025 | prnewswire.com

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

May 2, 2025 | prnewswire.com

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

April 28, 2025 | prnewswire.com

RedHill Biopharma receives non-compliance letter from Nasdaq

April 18, 2025 | markets.businessinsider.com

RedHill Biopharma Ltd.: RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

April 18, 2025 | finanznachrichten.de

RedHill Biopharma announces publication in journal on Opaganib

April 17, 2025 | markets.businessinsider.com

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

April 17, 2025 | prnewswire.com

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

April 16, 2025 | prnewswire.com

RedHill Biopharma Ltd.: RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

April 10, 2025 | finanznachrichten.de

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

April 10, 2025 | prnewswire.com

RedHill Biopharma to submit UK MAA for Talicia

March 18, 2025 | markets.businessinsider.com

RedHill to file FDA-approved Talicia for UK marketing

March 18, 2025 | thepharmaletter.comT

RedHill Biopharma Ltd.: RedHill Biopharma to Submit FDA-Approved Talicia for UK Marketing Authorisation

March 18, 2025 | finanznachrichten.de

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

March 18, 2025 | prnewswire.com

RedHill Biopharma announces plans to advance program for Crohn’s disease

March 13, 2025 | markets.businessinsider.com

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

March 12, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLSD, CBAY, EPIX, CYCN, and RDHL Company Descriptions

CymaBay Therapeutics NASDAQ:CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Clearside Biomedical NASDAQ:CLSD

$0.83 0.00 (-0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$0.82 0.00 (-0.53%)

As of 04:08 PM Eastern

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Cyclerion Therapeutics NASDAQ:CYCN

$3.26 -0.04 (-1.21%)

Closing price 03:59 PM Eastern

Extended Trading

$3.26 0.00 (-0.15%)

As of 04:20 PM Eastern

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

ESSA Pharma NASDAQ:EPIX

$1.87 +0.01 (+0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$1.86 -0.01 (-0.27%)

As of 04:27 PM Eastern

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Redhill Biopharma NASDAQ:RDHL

$1.91 -0.27 (-12.39%)

Closing price 03:59 PM Eastern

Extended Trading

$1.96 +0.05 (+2.36%)

As of 04:15 PM Eastern

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time